TRITON-PN Phase 3 Study Design and Rationale Presented at the 2026 Annual American Academy of Neurology (AAN) Meeting

20 Apr, 2026 TRITON-PN Phase 3 Study Design and Rationale Presented at the 2026 Annual American Academy of Neurology (AAN) Meeting

The design and rationale for the TRITON-PN Phase 3 study evaluating our third-generation investigational transthyretin (TTR) silencer, nucresiran, in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) was presented at AAN 2026.

Obici, et al. “Design and Rationale of TRITON-PN, a Phase 3 Study to Evaluate the Efficacy of Nucresiran in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy.”